Sponsor content
104 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryLivdelzi (seladelpar) is approved to treat primary biliary cholangitis (PBC) in adults in combination with ursodeoxycholic acid (UDCA) when UDCA alone isn't effective, or on its own if UDCA can’t be tolerated.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIVDELZI seladelpar 10 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YEYTUO lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YEYTUO lenacapavir (as sodium) 300 mg tablet bottle.
-
Cancellation by sponsorRequested by Gilead Sciences Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet bottle.
-
Prescription medicine registrationActive ingredients: bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate.
-
Jun-2025Prescription medicine evaluationActive ingredient: lenacapavir sodium.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HEPCLUDEX bulevirtide (as acetate) 2 mg powder for injection vial.
-
Jan-2025Prescription medicine evaluationActive ingredient: Seladelpar lysine dihydrate.